ARTICLE | Finance
Tecfidera upside?
Biogen ups guidance but stays mum on Tecfidera expectations
April 29, 2013 7:00 AM UTC
Investors liked what they heard about Biogen Idec Inc. (NASDAQ:BIIB) last week, sending the company's valuation up $2.4 billion by Friday's close.
On Monday, the stock rose $11.93 to $215.20, a $2.8 billion market cap gain, on early sales data reported by IMS Health for multiple sclerosis drug Tecfidera dimethyl fumarate (BG-12)...